• About Us
    • Contact Us
    • Login
    • ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • #GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
About Us Contact Us Login ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • 0 CME Hours
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • #GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
#Grand Rounds

Antenatal Corticosteroids Plus Magnesium Sulfate in Extreme Preterm: Neurodevelopmental Outcomes

image_pdfFavoriteLoadingFavorite

BACKGROUND AND PURPOSE:

  • Antenatal corticosteroids and magnesium sulfate are recommended for pregnancies at risk for preterm birth between 24w0d and 33w6d
    • Data regarding extreme preterm period are limited
  • Gentle et al. (Obstetrics & Gynecology, 2020) examined whether there was neurodevelopmental benefit for extremely preterm children (22w0d to 26w6d) with administration of corticosteroids and/or magnesium sulfate

METHODS:

  • Prospective observational study (2011 to 2014)
    • NICHD Neonatal Research Network
  • Participants
    • Children born at 22w0d to 26w6d weeks
  • Exposures
    • Antenatal corticosteroids and magnesium sulfate
    • Antenatal corticosteroids alone
    • Magnesium sulfate alone
    • Neither
  • Primary outcome
    • Severe neurodevelopmental impairment or death at 18 to 26 months age-corrected follow-up based on exposure to
      • Antenatal corticosteroids and magnesium sulfate
      • Antenatal corticosteroids alone
  • Secondary outcomes
    • Severe neurodevelopmental impairment or death based on exposure to
      • Antenatal corticosteroids and magnesium sulfate
      • Magnesium sulfate alone
      • Neither antenatal corticosteroids nor magnesium sulfate

RESULTS:

  • Total of 3093 children were included
    • Antenatal corticosteroids and magnesium sulfate: 72.5%
    • Antenatal corticosteroids alone: 16.4%
    • Magnesium sulfate alone: 2.9%
    • Neither: 8.1%
  • Children exposed to both antenatal corticosteroids and magnesium sulfate had a lower rate of severe neurodevelopmental impairment or death compared to either treatment alone, or neither
    • Antenatal corticosteroids and magnesium sulfate: 36.3%
    • Antenatal corticosteroids alone: 44.3%
      • Adjusted odds ratio (aOR) 0.73 (95% CI, 0.58 to 0.91)
    • Magnesium sulfate alone: 53%
      • aOR 0.49 (95% CI, 0.29 to 0.82)
    • Neither therapy: 48.2%
      • aOR 0.66, 95% CI 0.49 to 0.89
  • Children exposed to both antenatal corticosteroids and magnesium sulfate had a lower rate of death compared with either or neither therapy
    • The rate of severe neurodevelopmental impairment did not differ between exposure groups

CONCLUSION:

  • In this cohort of children born <27 weeks, a combination of antenatal treatment with both corticosteroids and magnesium sulfate was associated with lower rates of severe neurodevelopmental impairment or death vs corticosteroids alone
  • The authors state

Increased rates of magnesium sulfate exposure through quality improvement or other interventions may improve severe neurodevelopmental impairment or death without increasing the risk of neurodevelopmental impairment in survivors

Learn More – Primary Sources:

Association of Antenatal Corticosteroids and Magnesium Sulfate Therapy With Neurodevelopmental Outcome in Extremely Preterm Children

Now You Can Get ObG Clinical Research Summaries Direct to Your Phone, with ObGFirst

ObGFirst® – Try It Free! »

image_pdfFavoriteLoadingFavorite
< Previous
All #Grand Rounds Posts
Next >

Related ObG Topics:

Do Antenatal Corticosteroids Reduce Morbidity in Premature Neonates Prior to 24 weeks?
Antenatal Corticosteroids – When to Administer?
MgSO4 and Neuroprotection: What is the Relationship Between Maternal Dose and Fetal Levels?

Sections

  • COVID-19
  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • #Grand Rounds
  • My Bookshelf
  • Now@ObG
  • Media

ObG Library

  • Hysteroscopy
  • Fertility
  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Get Guideline Alerts Direct to Your Phone
Try ObGFirst Free!

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Log In to ObG First

Please log in to access OBGFirst and the 2T Ultrasound Atlas

Password Trouble?

Sign Up for ObGFirst

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!

ObG First Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site